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Stem cells, a special subset of cells derived from embryo or adult tissues, are known to present the
characteristics of self-renewal, multiple lineages of differentiation, high plastic capability, and long-term
maintenance. Recent reports have further suggested that neural stem cells (NSCs) derived from the adult
hippocampal and subventricular regions possess the utilizing potential to develop the transplantation
strategies and to screen the candidate agents for neurogenesis, neuroprotection, and neuroplasticity in
neurodegenerative diseases. In this article, we review the roles of NSCs and other stem cells in neuro-
protective and neurorestorative therapies for neurological and psychiatric diseases. We show the
evidences that NSCs play the key roles involved in the pathogenesis of several neurodegenerative
disorders, including depression, stroke, and Parkinson’s disease. Moreover, the potential and possible
utilities of induced pluripotent stem cells, reprogramming from adult ﬁbroblasts with ectopic expression
of four embryonic genes, are also reviewed and further discussed. An understanding of the biophysiology
of stem cells could help us elucidate the pathogenicity and develop new treatments for neurodegener-
ative disorders. In contrast to cell transplantation therapies, the application of stem cells can further
provide a platform for drug discovery and small molecular testing, including Chinese herbal medicines.
In addition, the high-throughput stem cell-based systems can be used to elucidate the mechanisms of
neuroprotective candidates in translation medical research for neurodegenerative diseases.
Copyright  2010, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
Open access under CC BY-NC-ND license.LLC.1. Introduction
Stemcells are classiﬁed into three typesaccording to theirabilities
to differentiate. The ﬁrst type is totipotent stem cells, which can be
implanted in the uterus of a living animal and give rise to a full
organism. The second type is pluripotent stem cells, such as embry-
onic stem(ES) cells and inducedpluripotent stem(iPS) cells. Theycan
give rise to every cell of an organism except extraembryonic tissues,
such as placenta. This limitation restricts pluripotent stem cells from
developing into a full organism. The third type is multipotent stem
cells. They are adult stem cells, which only generate speciﬁc lineagessearch and Education, Taipei
ai Road, Taipei 112, Taiwan,
u).
linical Gerontology & Geriatrics. Pof cells.1 ES cells are pluripotent stemcells derived from the inner cell
mass of mammalian blastocysts. They have remarkable abilities to
proliferate indeﬁnitely under appropriate in vitro culture system and
to differentiate into any cell types of all three germ layers.2,3 Since
isolation of human ES in 1998, ES cells have been regarded as
a powerful platform or tool for developmental studies, drug scre-
ening, diseases treatment, tissue repair engineering, and regenera-
tive medicine. However, two main limitations have impeded the
application of ES cell-based therapy. First, ethical dilemma regarding
the human embryo donation and destruction. Second, ES cells are
incompatible with the immune system of patients. To circumvent
these deﬁciencies, scientists worldwide have devoted to developing
a variety of reprogramming techniques to reverse somatic cells into
a stem cell-like state.4 In 2006, Takahashi and Yamanaka5 published
a landmark discovery that reprogramming of somatic cells back to
iPS cells could be achieved by retroviral transduction of fourublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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and Klf4. These iPS cells possessed morphological and molecular
features that resemble those of ES cells, as well as gave rise to tera-
toma and germline-competent chimeras on injection into blasto-
cysts. This amazing ﬁnding showed that cell fate could be
manipulated by certain genes and was recently honored by many
awards, including2009’sAlbert LaskerBasicMedicalResearchAward
and 2010’s International Balzan Prize. Since this astonishing report,
iPS cells are now generated by various ways, including kinds of
exogenous genes delivery methods,6e10 choosing multiple somatic
cell sources,11e15 and even by small compounds16 to improve the
efﬁciency of the reprogramming process.
2. Comparison of iPS cells with ES cells
Generally, fully reprogrammed iPS cells display numerous
properties similar to those of ES cells. First of all, iPS cells are
morphologically identical to ES cells and show inﬁnite proliferation
and self-renewal abilities. Several molecular and functional assays
were set to evaluate the similarity of iPS cells to ES cells, including
reactivation of self-renewal and pluripotency-associated genes,
telomerase activity, X chromosome, and stage-speciﬁc embryonic
surface antigens, suppression of somatic genes associated with cell
of origin, silencing of exogenous factors, capabilities of in vitro
differentiation, demethylation of promoters of pluripotency genes,
and in vivo teratoma formation, chimera contribution, germline
transmission, and tetraploid complementation.7,17 A recent study
demonstrated that patient-speciﬁc iPS cells from dermal ﬁbroblasts
of patients with long QT syndrome can differentiate into functional
cardiac myocytes but still recapitulated the electrophysiological
features of the disorder.18 Therefore, the major advantage of iPS
cells over ES cells is that iPS cells can be derived from a patient’s
own somatic cells, thereby avoiding immune rejection after trans-
plantation and the ethical concerns raised by using ES cells.
3. Advances in reprogramming techniques
Based on their pluripotent capability of differentiating into any
functional cell type, iPS cells possess great potential for regenera-
tive and therapeutic applications. However, the group led by Dr.
Yamanaka also reported that these chimeras derived from mouse
iPS cells and their progeny often develop tumors mainly because of
reactivation of c-Myc transgene.19 Thus, numerous approaches to
generate iPS cells with lower tumorigenicity have been established.
Several studies have shown that iPS cells generated without c-Myc
virus demonstrated reduced tumor incidence in chimeric mouse,
but the efﬁciency of iPS creation is signiﬁcantly reduced.20,21 To
overcome this dilemma, Nakagawa et al.22 found another member
of Myc, L-Myc, which possessed stronger activity to generate iPS
cells and less tumorigenic activity.
The use of genome-integrating retroviruses that are closely
related with tumor formation was another major limitation of the
original iPS cell generation techniques. Thus, reprogramming
strategies with nonintegrating systems seems to be solutions to
make iPS-based therapy feasible. In 2008, Stadtfeld et al.23 estab-
lished mouse iPS cells from ﬁbroblasts and liver cells by non-
integrating adenoviruses carrying four deﬁned factors, suggesting
that insertional mutagenesis is not required for in vitro reprogram-
ming. At the same time, Okita et al.24 successfully generated iPS cells
by transient transfection of two plasmids containing cDNAs
encoding four factors, eliminating transgenic integration by the use
of retroviruses. More recently, Somers et al.25 and Carey et al.26
individually described a “stem cell cassette” or a polycistronic
virus, a single lentiviral vector composed of all four factors, was able
to yield iPS with reduced insertional mutagenesis and viralreactivation. Another novel reprogramming technique using pig-
gyBac transposon was published.9,10,27 A polycistronic plasmid
harboring four factors and piggyBac transposon was constructed
and integrated into the genome in the presence of piggyBac trans-
posase. As the reprogramming process achieved, the inserted frag-
ment was easily removed by reexpressing transposase. The
transposon-based method eliminates the use of virus, displays
equivalent efﬁciencies to retroviral transduction, excises integrated
sequences without genome alteration, and therefore represents
a landmark progress toward therapeutically relevant virus-free iPS
cells. To avoid introducing exogenous genetic materials, two
amazing advances were reported. Zhou et al.28 demonstrated that
mouse ﬁbroblasts could be fully reprogrammed by direct delivery of
recombinant reprogramming proteins. In 2010, an impressive work
conducted byWarren et al.29 showed a strategy for reprogramming
by administration of synthetic mRNAs that code for key factors and
created RNA-iPS cells. Both techniques are safer, simpler, and faster
approaches than the currently established genetic method.
4. Reactive oxygen species and stem cells differentiation
High efﬁciency of iPS cells reprogramming/differentiation is
required in clinical application. Many studies have reported that
reactive oxygen species (ROS) play a critical role in mediating iPS
cells or stem cells reprogramming/differentiation.30,31 Intracellular
ROS serves as a second messenger in signaling transduction path-
ways. They are produced in vascular cells by a number of oxidases,
such as the NADPH oxidases and xanthine oxidase, lipoxygenases,
cytochrome p450, and uncoupling of the mitochondrial respiratory
chain.32 iPS cells have similar function in stress defense mecha-
nisms and mitochondrial regulation with human ES cells.33 Fran-
cisco et al.34 had revealed that high glucose promoted stem cell
differentiation into cardiomyocyte by activating NADPH oxidase as
well as increasing intracellular ROS level. Ji et al.35 had reported
ROS-enhanced stem cell differentiation via mediating extracellular
signal-regulated kinase/c-Jun N-terminal kinase, P38 mitogen-
activated protein kinase, and protein kinase B. Furthermore, Varum
et al.36 had shown that attenuating the mitochondrial respiratory
chain can increase pluripotency in human ES cells by facilitating
intracellular ROS generation. Moreover, generation of ROS and the
activities of antioxidant enzymes must be mainly manipulated to
preserve the homeostasis of the intracellular redox status. Intra-
cellular antioxidant enzymes, such as superoxide dismutase (SOD),
catalase, and glutathione peroxidase, play an important role to
mitigate oxidative stress, such as SODs protect against superoxide-
mediated cytotoxicity by catalyzing O2 to form H2O2. SOD is inac-
tivated by H2O2 formed by repressing of the superoxide anion.37
Not only ROS level is activated but also intracellular antioxidant
enzymes are mediated during differentiation. Chen et al.38 had
validated that intracellular antioxidant enzymes, mitochondrial
mass, as well as oxygen consumption rate were increased during
differentiation in human mesenchymal stem cells.
5. Clinical application of iPS cells
5.1. iPS cells in the diseases of central nervous system
The development of stem cell studies makes cell transplantation
a promising therapy for the diseases of central nervous system,
including stroke, traumatic brain injury, hypoxic encephalopathy,
and degenerative disorders.39 Parkinson’s disease (PD) is the best
candidate for the cell replacement therapy because only one group
of cells are affected, which are dopaminergic neurons. The main
pathology of PD is cellular loss of the substantia nigra pars com-
pacta dopaminergic neurons that project to the striatum.40 Clinical
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are evident when about 80% of striatal and 50% of nigral neurons
are lost.41 The ﬁrst attempt of cell replacement therapy was to use
fetal mesencephalic tissue, and the results were successful in the
earliest reports.39,42,43 However, adverse effects and limitations
were revealed in the following studies, which included off-medi-
cation dyskinesia,44e46 graft-induced inﬂammatory responses,47
and limited tissue availability.39
Graft-induced dyskinesia may be caused by unfavorable compo-
sition of the fetal mesencephalic grafts. The fetal mesencephalic
tissue includes not only dopaminergic but also nondopaminergic
neurons.39 The exclusion of serotonin and g-aminobutyric acid
neurons and enrichment of substantia nigra dopaminergic neurons
will decrease the occurrence of dyskinesia.47 Stem cells are ideal cell
sources to achieve this goal. Recent evidence has shown that dopa-
minergic neurons derived from ES cells and bone marrow-derived
neural progenitors are functional when grafted into parkinsonian
rats.48,49 Several methods are able to improve the effectiveness of
midbraindopaminergicneurongeneration fromstemcells, including
manipulating transcription factor (e.g., Nurr1, Pitx3, or Lmx1a),
coculture with astrocytes, and using ﬂuorescence-activated cell
sorting.47 The ability of deriving large quantities of correctly differ-
entiated dopamine neurons makes stem cells a good cell sources for
transplantation in PD.
Cell replacement therapy is more complicated for stroke, brain
injury, and other degenerative diseases, such as Alzheimer’s
disease. The difﬁculties are because of variable cell types involved,
which include neurons, astrocytes, oligodendrocytes, and endo-
thelial cells of blood vessels.50 ES cells have been demonstrated to
have good developmental potential and signiﬁcant survival rate
after transplantation into the brain.51 Transplantation of ES cells
also recovered behavioral dysfunction induced by middle cerebral
arterial occlusion in an animal model.52 However, the ethical
consideration, the limited availability, and the possibility of
immune rejection after transplantation restrict the accessibility of
ES cells.
Because iPS cells are derived from the somatic cells, potential
immune rejection and ethical consideration can be avoided.
Recently, Wernig et al.53 demonstrated that neurons and glial cells
could be derived from iPS cells in vitro, and that transplantation of
iPS cell-derived neurons into brainwas able to improve behavior in
a rat model of PD. We also demonstrated an efﬁcient method to
differentiate iPS cells into astrocyte-like and neuron-like cells,
which displayed functional electrophysiological properties. Our in
vivo study showed that direct injection of iPS cells into damaged
areas of rat cortex signiﬁcantly decreased the infarct size, improved
the motor function, attenuated inﬂammatory cytokines, and
mediated neuroprotection after middle cerebral artery occlusion.
Subdural injection of iPS cells with ﬁbrin gluewas as effective as the
direct-injection method and provided a safer choice for cell
replacement therapy.54
Teratoma or tumor formation is a major adverse effect of cell
transplantation using ES or iPS cells.55 One of the methods to
prevent teratoma/tumor formation is elimination of nonneural
progenitors, which can be achieved by the elaboration of differ-
entiation protocols that allow maximal homogeneity of the trans-
plant56 or by cell sorting before transplantation.57 Exclusion of
poorly differentiated ES or iPS cells can also reduce the rate of
teratoma or tumor formation.58 Some antioxidants may prevent
tumorigenesis after cell transplantation. Resveratrol, a natural
polyphenol antioxidant, is demonstrated that it can inhibit tera-
toma formation in vivo.59 Our recent study also found that doco-
sahexaenoic acid can inhibit teratoma formation in addition to
promoting dopaminergic differentiation in iPS cells in PD-like
rats.60 It has been only two years since the development of iPS cells.Enhancement of effectiveness and eliminating adverse effects of
this cell transplantation therapy required more extensive studies.
5.2. iPS cells in cardiovascular diseases
In the aging population of a modern world, cardiovascular
diseases are major medical problems because they usually cause
morbidity andmortality.1 The treatments of cardiovascular diseases
include medication, surgical intervention, rehabilitation, exercise
programs, and transplantation.61 There are several side effects,
complications, and limitations of transplantation therapy, such as
immunological reaction, infection, and limited availability.62 A new
hope in cardiovascular regenerative medicine has been revealed
since Doetschman et al.63 successfully induced mouse ES cells
differentiating into cardiomyocytes in vitro in 1985. Many studies
had reported facilitated differentiation from ES cells or iPS cells into
cardiomyocytes, endothelial vascular cells, and smooth muscle
cells.64,65 In animal models, cardiovascular regeneration therapy
markedly attenuated ventricular wall thinning as well as enhanced
contractility of cardiomyocytes postligation of the left anterior
descending artery,66 restored the function of heart and electric
stability after myocardial infarction,67 and enriched the formation
of small capillaries and venules.68
5.3. iPS cells in lung diseases
Acute lung injury (ALI) is characterized by neutrophil accumu-
lation in the lungs, interstitial edema, disruption of epithelial
integrity, and leakage of proteins into the alveolar space.69e72
Infection, associated with endotoxemia and blood loss are
frequent predisposing factors to the development of ALI69; and in
experimental settings, endotoxemia produces ALI. Neutrophils play
a central role in this acute pulmonary inﬂammatory process as their
elimination can prevent the development of ALI.73 The neutrophils
present in the lungs during ALI produce inﬂammatory mediators,
including cytokines, such as interleukin-6 and macrophage
inﬂammatory peptide-2, and demonstrate increased activation of
transcriptional regulatory factors, including nuclear factor-kB
(NF-kB).73e76
Bindingelements forNF-kBarepresent in the enhancer/promoter
regions of cytokine genes, such as interleukin-1b, macrophage
inﬂammatorypeptide-2, and tumornecrosis factor-a, aswell asother
important immunoregulatory molecules, such as intercellular
adhesionmolecule-1 andcomplementC4protein.77 InhibitionofNF-
kB activation prevents endotoxin-induced increases in proinﬂa-
mmatory cytokine expression in the lungs.76
iPS cell administration improved the impairment of pulmonary
function in endotoxin-induced ALI, including airway resistance
(enhanced pause), lung tidal volumes, and arterial partial oxygen
pressure levels. Hypoxemia is the major symptom and sign of ALI,
no matter whether in the mice model or in human cases. The effect
of iPS cell treatment was to rescue the hypoxemia, similar to
another study using a therapeutic agent in an animal model of lung
injury.78 A recent study found that transplantation of human ES
cells abrogated bleomycin-induced lung injury inmice and restored
blood arterial oxygen saturation and lung tidal volume.79 Our study
showed that the intravenous injection of iPS cells led to recovery of
the impairment of both airway resistance and lung tidal volume
induced by the instillation of endotoxin intratracheally. In a pre-
vious mice model of early ALI, most changes in bronchoalveolar
lavage suggestive of acute pulmonary irritation were compatible
with the changes in pulmonary function, such as airway resistance
(enhanced pause) and tidal volume.80 Thus, iPS cell therapy not
only abolished endotoxin-induced lung injury in mice but also
improved the changes in pulmonary physiological function. This
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by overcoming the immune rejection and the ethical controversy
over the use of ES cells and mesenchymal stem cells.
5.4. iPS in liver diseases
Liver diseases and liver injuries are common health problems
throughout the world. The loss of functional liver tissue after injury
will activate a wound healing process aimed to repair and restore
the integrity of the injured liver. Intense or uncontrollable insults
could efface the healing response and result in end-stage liver
disease, which is irreversibly associated with liver failure. Curr-
ently, orthotopic liver transplantation is the most effective therapy
for acute and chronic liver failure. However, it is limited by shortage
of donors, operative risk, lifelong use of immunosuppressive
agents, and very high costs. The development and application of
cell therapies has been attempted to treat different forms of liver
diseases.81e86 Cell therapy has been considered as a potential
therapeutic alternative to orthotopic liver transplantation.87e89 It
has minimal invasive procedures and fewer surgical comp-
lications.90e92 These cells, particularly the stem cell population,
appeared very attractive and have gained considerable attention for
its potential to supportive tissue regeneration. Besides, they have
the potential to generate large amounts of donor cells available for
transplant or to be stored for future use.
Although previous studies using stem cells in the treatment of
liver diseases have shown beneﬁcial effects, the underlying mech-
anisms accounting for their therapeutic effects have not been
completely revealed. One of the possible explanations is that the
transplanted stem cells generate cells that function as normal
hepatocytes. However, it has been noticed that the percentage of
liver repopulation remains very low despite efforts to improve cell
engraftment. Another explanation is the indirect paracrine effects
that initiated in the damaged liver after stem cell transplant.93
Some soluble factors could have been secreted to facilitate the
process of repair and regeneration. It is still unclear how these
soluble factors regulate the recovery process in the injured liver
after stem cell transplantation.
Currently, the therapeutic roles of iPS cell or iPS-derived hepa-
tocytes (IDHs)-like cells for liver injury have gained increasing
attention.94,95 Si-Tayeb et al.94 reported that human iPS cells from
foreskin ﬁbroblasts could be used to efﬁciently generate human
hepatocyte-like cells. The IDHs-like cells displayed several hepatic
functions, including albumin expression, accumulation of glycogen,
metabolism of indocyanine green, accumulation of lipid, active
uptake of low-density lipoprotein, synthesis of urea, and expressed
the same hepatocyte mRNA ﬁngerprint. However, the levels of
expression of these enzymes were lower in most cases when
compared with adult liver samples, suggesting that although
hepatocyte-like cells derived from human iPS cells have differen-
tiated to a state that supports many hepatic activities, they do not
entirely recapitulate mature liver function. Similarly, it is not clear
that whether iPS cells and IDHs have the homing characteristic of
locating the area of acute hepatic failure and further can rescue the
liver function.
6. Summary
In the past, scientists tried to ameliorate the injury through
transplantation of target cells- or stem cells-derived precursors.
However, it is hard to prepare enough amounts of target cells in
vitro or to efﬁciently isolate differentiated cells from stem cell
populations. The generation of iPS cells stands a better chance than
other reprogramming procedures (somatic cell nuclear transfer, cell
fusion, and so forth) of overcoming these issues, whereas a largenumber of iPS cells can be prepared in vitro. To date, iPS-derived
strategies have been applied to four disease models, sickle cell
anemia, PD, hemophilia A, and acute myocardial infarction. How-
ever, there still exist several questions to be answered, such as what
are the detailed molecular mechanisms of reprogramming? Can iPS
cells be generated solely by chemical compounds like epigenetic
modiﬁer without DNA transduction? How to improve the yield of
iPS? In addition, to provide replacement cells for therapy, a new cell
by lineage switching or direct conversion from a normal somatic
cell should also be considered.96 In conclusion, the iPS techniques
open a new era for stem cell research and offer promising oppor-
tunities for patient-speciﬁc pluripotent cell-based regenerative
medicine.
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